BioNTech SE ADR (BNTX): Price and Financial Metrics


BioNTech SE ADR (BNTX): $143.41

2.92 (+2.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BNTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BNTX POWR Grades

  • Value is the dimension where BNTX ranks best; there it ranks ahead of 98.67% of US stocks.
  • The strongest trend for BNTX is in Sentiment, which has been heading up over the past 179 days.
  • BNTX's current lowest rank is in the Growth metric (where it is better than 2.85% of US stocks).

BNTX Stock Summary

  • With a market capitalization of $34,851,385,767, BIONTECH SE has a greater market value than 93.17% of US stocks.
  • BNTX's current price/earnings ratio is 3.44, which is higher than just 5.13% of US stocks with positive earnings.
  • With a year-over-year growth in debt of -46.62%, BIONTECH SE's debt growth rate surpasses just 5.95% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BIONTECH SE are MX, UTSI, RVMD, CKPT, and HGEN.
  • Visit BNTX's SEC page to see the company's official filings. To visit the company's web site, go to www.biontech.de.

BNTX Stock Price Chart Interactive Chart >

Price chart for BNTX

BNTX Price/Volume Stats

Current price $143.41 52-week high $189.07
Prev. close $140.49 52-week low $117.08
Day low $138.05 Volume 1,248,600
Day high $144.73 Avg. volume 803,005
50-day MA $158.20 Dividend yield N/A
200-day MA $151.44 Market Cap 34.80B

BioNTech SE ADR (BNTX) Company Bio


BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek [2] short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. (Source:Wikipedia)


BNTX Latest News Stream


Event/Time News Detail
Loading, please wait...

BNTX Latest Social Stream


Loading social stream, please wait...

View Full BNTX Social Stream

Latest BNTX News From Around the Web

Below are the latest news stories about BIONTECH SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.

Thursday Predictions: 3 Hot Stocks for Tomorrow

Airline stocks, credit card stocks, and vaccine stocks are our focus when it comes to the hot stocks for tomorrow.

Bret Kenwell on InvestorPlace | January 25, 2023

12 Cheap Biotech Stocks To Buy

In this article, we will be taking a look at 12 cheap biotech stocks to buy. To skip our detailed analysis of the biotech sector, you can go directly to see 5 Cheap Biotech Stocks To Buy. The biotechnology sector has been on the rise over the past three decades. Several forecasts expect the sector […]

Yahoo | January 25, 2023

Is Weakness In BioNTech SE (NASDAQ:BNTX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

With its stock down 19% over the past month, it is easy to disregard BioNTech (NASDAQ:BNTX). But if you pay close...

Yahoo | January 23, 2023

Israel Says No Stroke Risk Associated With Pfizer/BioNTech Updated COVID-19 Shots

Israel health ministry official said Isreal had not identified any evidence linking strokes to an updated coronavirus vaccine by Pfizer Inc (NYSE: PFE ) and BioNTech SE (NASDAQ: BNTX ). "We have not turned up such a finding, even after we went back and rechecked all our data after the FDA announcement," Salman Zarka, the head of Israel''s coronavirus task force, said in a video briefing Full story available on Benzinga.com

Benzinga | January 20, 2023

Israel not found link between Pfizer Covid shot and stroke

Israel has not identified any evidence linking strokes to an updated coronavirus vaccine made by U.S. drugmaker Pfizer and its German partner BioNTech, according to a health ministry official. On Friday, the U.S. Food and Drug Administration (FDA) and the Centres for Disease Control and Prevention said that a safety…

Cyprus Mail | January 19, 2023

Read More 'BNTX' Stories Here

BNTX Price Returns

1-mo N/A
3-mo -1.27%
6-mo -21.68%
1-year -18.60%
3-year 400.52%
5-year N/A
YTD -4.53%
2022 -40.60%
2021 216.24%
2020 140.61%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6879 seconds.